See more : Global-Dining, Inc. (7625.T) Income Statement Analysis – Financial Results
Complete financial analysis of Jaguar Health, Inc. (JAGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jaguar Health, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Chesapeake Energy Corporation (CHKEL) Income Statement Analysis – Financial Results
- Okaya Electric Industries Co., Ltd. (6926.T) Income Statement Analysis – Financial Results
- Turkiye Garanti Bankasi A.S. (TKGBY) Income Statement Analysis – Financial Results
- Bumrungrad Hospital Public Company Limited (BUGDF) Income Statement Analysis – Financial Results
- BCE Inc. (BCEPF) Income Statement Analysis – Financial Results
Jaguar Health, Inc. (JAGX)
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.76M | 11.96M | 4.34M | 9.39M | 5.78M | 4.42M | 4.36M | 141.52K | 258.38K | 0.00 |
| Cost of Revenue | 2.04M | 2.02M | 2.33M | 3.28M | 3.82M | 2.77M | 880.41K | 51.97K | 123.46K | 0.00 |
| Gross Profit | 7.72M | 9.94M | 2.00M | 6.11M | 1.96M | 1.65M | 3.48M | 89.56K | 134.92K | 0.00 |
| Gross Profit Ratio | 79.13% | 83.11% | 46.18% | 65.05% | 33.93% | 37.37% | 79.81% | 63.28% | 52.22% | 0.00% |
| Research & Development | 18.60M | 17.65M | 15.08M | 6.41M | 5.82M | 5.15M | 4.27M | 7.21M | 6.48M | 4.22M |
| General & Administrative | 16.59M | 17.87M | 17.10M | 14.39M | 13.50M | 12.28M | 11.25M | 5.98M | 5.34M | 0.00 |
| Selling & Marketing | 6.46M | 8.84M | 8.89M | 6.61M | 6.94M | 9.83M | 3.08M | 485.44K | 765.09K | 0.00 |
| SG&A | 23.05M | 26.71M | 26.00M | 21.00M | 20.44M | 22.11M | 14.33M | 6.47M | 6.10M | 4.10M |
| Other Expenses | 371.00K | 950.00K | -765.00K | 190.00K | 648.80K | 315.69K | 88.55K | -11.05K | -27.28K | 0.00 |
| Operating Expenses | 42.02M | 44.35M | 41.08M | 27.41M | 26.91M | 27.26M | 18.60M | 13.68M | 12.58M | 8.32M |
| Cost & Expenses | 44.05M | 46.37M | 43.41M | 30.69M | 30.72M | 30.03M | 19.48M | 13.73M | 12.70M | 8.32M |
| Interest Income | 0.00 | 12.72M | 8.42M | 2.79M | 5.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.38M | 12.72M | 8.42M | 2.79M | 5.73M | 2.63M | 1.21M | 985.55K | 3.32M | 0.00 |
| Depreciation & Amortization | 1.16M | 2.29M | 1.83M | 2.28M | 1.93M | 1.75M | 584.34K | 47.49K | 5.16K | -51.42K |
| EBITDA | -33.13M | -33.38M | -42.35M | -28.74M | -30.87M | -27.77M | -11.13M | -13.70M | -12.97M | -8.37M |
| EBITDA Ratio | -339.42% | -260.73% | -914.88% | -257.61% | -397.20% | -454.56% | 100.27% | -9,459.45% | -4,620.54% | 0.00% |
| Operating Income | -34.29M | -34.42M | -39.07M | -21.30M | -24.95M | -30.82M | -34.25M | -13.59M | -12.45M | -8.32M |
| Operating Income Ratio | -351.31% | -287.85% | -901.36% | -227.00% | -431.98% | -697.98% | -785.27% | -9,599.84% | -4,816.67% | 0.00% |
| Total Other Income/Expenses | -7.61M | -13.98M | -11.89M | -7.16M | -9.58M | -1.32M | -902.80K | -1.15M | -3.85M | -293.91K |
| Income Before Tax | -41.90M | -48.40M | -52.60M | -33.81M | -38.53M | -32.15M | -35.15M | -14.73M | -16.29M | -8.61M |
| Income Before Tax Ratio | -429.27% | -404.78% | -1,213.38% | -360.25% | -667.15% | -727.92% | -805.97% | -10,410.87% | -6,305.24% | 0.00% |
| Income Tax Expense | 0.00 | -941.00K | 7.65M | 2.98M | 10.00K | -1.28M | -13.18M | 1.14M | 3.82M | 345.34K |
| Net Income | -41.30M | -47.45M | -60.25M | -36.79M | -38.54M | -32.15M | -21.97M | -14.73M | -16.29M | -8.61M |
| Net Income Ratio | -423.11% | -396.91% | -1,389.87% | -392.02% | -667.32% | -727.92% | -503.73% | -10,410.87% | -6,305.24% | 0.00% |
| EPS | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| EPS Diluted | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| Weighted Avg Shares Out | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
| Weighted Avg Shares Out (Dil) | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
US Stocks Mixed; Li Auto Shares Plummet After Q1 Results
Why Is Jaguar Health (JAGX) Stock Down 40% Today?
Jaguar Health, Inc. Announces Reverse Stock Split
Jaguar Health Reports First Quarter 2024 Financial Results
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Want $10,000? Invest $1,000 in These 3 Penny Stocks Now
Source: https://incomestatements.info
Category: Stock Reports